13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001346824
Total reported value
$11.5B
$11.5B
63 檔
25.9%
As reported in its official Q2 2025 Form 13F filing, Ra Capital Management, L.p.'s tracked investment portfolio stood at $11.5B with 63 total positions.
In Q2 2025, Ra Capital Management, L.p. adopted a defensive or profit-taking posture, trimming 9 positions and completely liquidating 28 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ASND | Ascendis Pharma A/S | Stock-Other | 29.90% | -24.92% | EXIT | |
| 2 | PCVX | Vaxcyte Inc | Stock-Other | 6.55% | -1.27% | -1.83% | |
| 3 | RYTM | Rhythm Pharmaceuticals Inc | Stock-Other | 5.92% | +0.29% | -8.60% | |
| 4 | JANX | Janux Therapeutics Inc | Stock-Other | 4.35% | -0.16% | — | |
| 5 | RNAGBP | Avidity Biosciences Inc | Stock-Other | 3.48% | — | +15.33% | |
| 6 | ACLXGBX | Arcellx Inc | Stock-Other | 3.37% | — | — | |
| 7 | ETNBGBP | 89bio Inc | Stock-Other | 3.29% | — | — | |
| 8 | SPRY | Ars Pharmaceuticals Inc | Stock-Other | 3.19% | -0.16% | — | |
| 9 | NAMS | NewAmsterdam Pharma Company N.V. | Stock-Other | 3.09% | -0.43% | — | |
| 10 | SION | Sionna Therapeutics Inc | Stock-Other | 3.05% | -0.42% | — | |
| 11 | CDTX | Cidara Therapeutics Inc | Stock-Other | 2.76% | — | +207.97% | |
| 12 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 2.19% | -0.52% | +11.15% | |
| 13 | LENZ | Lenz Therapeutics Inc | Stock-Other | 2.06% | -0.20% | — | |
| 14 | WVE | Wave Life Sciences Ltd. | Stock-Other | 1.99% | -0.71% | — | |
| 15 | TYRA | Tyra Biosciences Inc | Stock-Other | 1.97% | -1.56% | +14.68% | |
| 16 | GHRS | GH Research PLC | Stock-Other | 1.58% | +0.64% | +10.54% | |
| 17 | DYN | Dyne Therapeutics Inc | Stock-Other | 1.56% | — | — | |
| 18 | GERN | Geron CORP | Stock-Other | 1.43% | -0.53% | — | |
| 19 | IRON | Disc Medicine Inc | Stock-Other | 1.41% | -0.10% | — | |
| 20 | MLYS | Mineralys Therapeutics Inc | Stock-Other | 1.40% | -0.41% | — | |
| 21 | SEPN | Septerna Inc | Stock-Other | 1.25% | +0.26% | — | |
| 22 | FULC | Fulcrum Therapeutics Inc | Stock-Other | 1.19% | -0.49% | EXIT | |
| 23 | BCAX | Bicara Therapeutics Inc | Stock-Other | 1.09% | +0.34% | — | |
| 24 | VOR | Vor Biopharma Inc. | Stock-Other | 1.08% | — | — | |
| 25 | TSHA | Taysha Gene Therapies Inc | Stock-Other | 0.92% | +0.27% | +116.65% | |
| 26 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 0.90% | -2.32% | EXIT | |
| 27 | RXST | Rxsight Inc | Stock-Other | 0.81% | — | -1.07% | |
| 28 | TRML | Tourmaline Bio Inc | Stock-Other | 0.68% | — | — | |
| 29 | SRRK | Scholar Rock Holding CORP | Stock-Other | 0.68% | — | — | |
| 30 | CLYM | Climb Bio Inc | Stock-Other | 0.66% | +0.46% | — | |
| 31 | GPCR | Structure Therapeutics Inc | Stock-Other | 0.53% | — | — | |
| 32 | SLDB | Solid Biosciences Inc | Stock-Other | 0.48% | +0.33% | +34.20% | |
| 33 | ✓ | Stock-Other | 0.32% | — | — | ||
| 34 | MNPR | Monopar Therapeutics Inc | Stock-Other | 0.31% | +0.15% | — | |
| 35 | NKTX | Nkarta Inc | Stock-Other | 0.30% | +0.03% | — | |
| 36 | LRMR | Larimar Therapeutics Inc | Stock-Other | 0.29% | — | — | |
| 37 | ABOS | Acumen Pharmaceuticals Inc | Stock-Other | 0.29% | -0.03% | — | |
| 38 | ELVN | Enliven Therapeutics Inc | Stock-Other | 0.29% | — | — | |
| 39 | TVTX | Travere Therapeutics Inc | Stock-Other | 0.29% | -0.24% | EXIT | |
| 40 | FDMT | 4d Molecular Therapeutics In | Stock-Other | 0.29% | +0.08% | — | |
| 41 | HNGE | Hinge Health Inc-a | Stock-Other | 0.26% | -0.15% | EXIT | |
| 42 | ARTV | Artiva Biotherapeutics Inc | Stock-Other | 0.25% | +0.84% | — | |
| 43 | PEPG | Pepgen Inc | Stock-Other | 0.20% | -0.07% | — | |
| 44 | JBIO | Jade Biosciences Inc | Stock-Other | 0.18% | +0.16% | — | |
| 45 | TNGX | Tango Therapeutics Inc | Stock-Other | 0.17% | — | — | |
| 46 | ACRV | Acrivon Therapeutics Inc | Stock-Other | 0.17% | +0.07% | — | |
| 47 | ELDN | Eledon Pharmaceuticals Inc | Stock-Other | 0.16% | — | — | |
| 48 | RCUS | Arcus Biosciences Inc | Stock-Other | 0.16% | — | — | |
| 49 | ✓ | Stock-Other | 0.13% | -0.02% | — | ||
| 50 | OMDA | Omada Health Inc | Stock-Other | 0.12% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | ASND | Ascendis Pharma A/S | +3.1% | — | Unchanged |
| 2 | CDTX | Cidara Therapeutics Inc | +2.4% | +207.97% | Add |
| 3 | SION | Sionna Therapeutics Inc | +1.2% | — | Unchanged |
| 4 | SPRY | Ars Pharmaceuticals Inc | +0.9% | — | Unchanged |
| 5 | ETNBGBP | 89bio Inc | +0.9% | — | Unchanged |
| 6 | FULC | Fulcrum Therapeutics Inc | +0.7% | — | Unchanged |
| 7 | TSHA | Taysha Gene Therapies Inc | +0.7% | +116.65% | Add |
| 8 | VOR | Vor Biopharma Inc. | +0.6% | — | Unchanged |
| 9 | SEPN | Septerna Inc | +0.6% | — | Unchanged |
| 10 | RYTM | Rhythm Pharmaceuticals Inc | +0.5% | -8.60% | Trim |
| 11 | RNAGBP | Avidity Biosciences Inc | +0.4% | +15.33% | Add |
| 12 | TYRA | Tyra Biosciences Inc | +0.3% | +14.68% | Add |
| 13 | GHRS | GH Research PLC | +0.3% | +10.54% | Add |
| 14 | LENZ | Lenz Therapeutics Inc | +0.3% | — | Unchanged |
| 15 | HNGE | Hinge Health Inc-a | +0.3% | NEW | New buy |
| 16 | SLDB | Solid Biosciences Inc | +0.2% | +34.20% | Add |
| 17 | JBIO | Jade Biosciences Inc | +0.2% | NEW | New buy |
| 18 | TNGX | Tango Therapeutics Inc | +0.2% | NEW | New buy |
| 19 | OMDA | Omada Health Inc | +0.1% | NEW | New buy |
| 20 | IRON | Disc Medicine Inc | +0.1% | — | Unchanged |
| 21 | CTMX | Cytomx Therapeutics Inc | +0.1% | +166.13% | Add |
| 22 | WGS | Genedx Holdings CORP | +0.1% | NEW | New buy |
| 23 | GPCR | Structure Therapeutics Inc | +0.1% | — | Unchanged |
| 24 | LRMR | Larimar Therapeutics Inc | +0.1% | — | Unchanged |
| 25 | SRRK | Scholar Rock Holding CORP | +0.1% | — | Unchanged |
| 26 | FDMT | 4d Molecular Therapeutics In | 0% | — | Unchanged |
| 27 | TRML | Tourmaline Bio Inc | 0% | — | Unchanged |
| 28 | ACLXGBX | Arcellx Inc | 0% | — | Unchanged |
| 29 | IFRX | InflaRx N.V. | 0% | NEW | New buy |
| 30 | DNTH | Dianthus Therapeutics Inc | 0% | — | Unchanged |
| 31 | HOWL | Werewolf Therapeutics Inc | 0% | +8.73% | Add |
| 32 | BBNX | Beta Bionics Inc | 0% | — | Unchanged |
| 33 | ABOS | Acumen Pharmaceuticals Inc | 0% | — | Unchanged |
| 34 | CLYM | Climb Bio Inc | 0% | — | Unchanged |
| 35 | ✓ | 0% | — | Unchanged | |
| 36 | RCUS | Arcus Biosciences Inc | 0% | — | Unchanged |
| 37 | ELVN | Enliven Therapeutics Inc | 0% | — | Unchanged |
| 38 | MNPR | Monopar Therapeutics Inc | — | — | Unchanged |
| 39 | SCLXUSD | Scilex Holding Co | — | EXIT | Sold out |
| 40 | ✓ | — | — | Unchanged | |
| 41 | ✓ | Newamsterdam Pharma Company | 0% | — | Unchanged |
| 42 | TORCEUR | Adicet Bio Inc | 0% | — | Unchanged |
| 43 | NKTX | Nkarta Inc | 0% | — | Unchanged |
| 44 | LXEO | Lexeo Therapeutics Inc | 0% | EXIT | Sold out |
| 45 | SRZN | Surrozen Inc | 0% | -11.27% | Trim |
| 46 | ELDN | Eledon Pharmaceuticals Inc | 0% | — | Unchanged |
| 47 | TVTX | Travere Therapeutics Inc | -0.1% | — | Unchanged |
| 48 | PEPG | Pepgen Inc | -0.1% | — | Unchanged |
| 49 | AVTX | Avalo Therapeutics Inc | -0.1% | -3.52% | Trim |
| 50 | STRO | Sutro Biopharma, Inc. | -0.1% | EXIT | Sold out |
According to official SEC Form 13F filings, Ra Capital Management, L.p. reported a total U.S. public equity portfolio value of $11.5B across 63 disclosed positions in Q2 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including ASND, PCVX, RYTM) accounted for 25.9% of total reported equity market value during Q2 2025.
Top New Position Initiated
HNGE
市值: $15.5M
Top Position Liquidated / Trimmed
APGE
前期市值: $58.6M
During Q2 2025, Ra Capital Management, L.p.'s top holdings by market value included ASND (29.9%)、PCVX (6.5%)、RYTM (5.9%). The largest single position, ASND, represented 29.9% of total portfolio value.
In Q2 2025, Ra Capital Management, L.p. made 52 total portfolio adjustments, initiating 6 new buys, adding to 9 positions, trimming 9 holdings, and fully liquidating 28 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.